Revenue segments as reported by the company.

Companion Animal

Livestock

Contract Manufacturing & Human Health

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Interest expense

Other (income)/deductions–net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zoetis

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests, and precision livestock farming technology. The firm operates through the following segments: United States & International. Its products include vaccines, parasiticides, anti-infectives, dermatology products, medicated feed additives, animal health diagnostics, and other pharmaceutical products for both companion animal and livestock customers. The company was founded in 1952 and is headquartered in Parsippany, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zoetis reports robust 2022 results, eyes growth in key markets

Zoetis delivered strong financial performance in 2022 and projects continued growth in 2023. The company's investments in R&D, CapEx, and customer engagement strategies position it well for future competition. Challenges from inflation, competition, and supply chain issues require careful navigation, but opportunities in key growth areas offer potential for sustained success.

Zoetis reports solid Q1 results, reaffirms full-year guidance

Zoetis delivered solid Q1 results despite challenges in certain segments. The company remains optimistic about future growth opportunities, supported by upcoming product launches and strategic investments. Investor Day will provide detailed insights into Zoetis' growth strategy and innovation pipeline.

Zoetis reports robust Q2 earnings, eyes global market expansion

Zoetis delivered strong financial results in Q2 2023, with expectations of continued growth in operational revenue and adjusted net income for the full year. The company remains focused on driving revenue growth through industry tailwinds and innovation over the next few years.

Zoetis reports robust Q3 performance and anticipates accelerated growth

Zoetis' Q3 2023 performance reflects strong revenue and income growth, supported by successful product launches and a robust diagnostics portfolio.
While facing challenges from upcoming competition and margin pressures, the company remains confident in its growth prospects for 2023 and 2024.
Opportunities lie in accelerated growth driven by key products, macro trends in animal health, and ongoing investments in innovation and cost management.
Overall, Zoetis' strategic strengths position it well to navigate challenges and capitalize on opportunities for sustained growth and value creation.

Zoetis reports robust 2023 results and sets sights on international growth

Zoetis delivered strong financial performance in 2023, driven by innovative products and operational growth across portfolios. The company is well-positioned for continued growth in 2024, focusing on innovation, market leadership, and addressing challenges like currency dynamics and capacity constraints. Opportunities lie in international markets, DTC initiatives, and sustained revenue growth.

Zoetis excels in Q1 with double-digit growth and strategic focus

Zoetis' Q1 performance reflects strong revenue and income growth, driven by successful product launches and market leadership. The company's focus on innovation, quality, and strategic divestments positions it well for future growth. Challenges in livestock and competition require strategic adaptation, while opportunities in product growth and market expansion offer promising avenues for development.

Zoetis excels in Q2 2024, raises guidance and announces buyback

Zoetis' Q2 2024 performance highlights its strong market position, driven by innovative products and strategic initiatives. While challenges exist in the competitive landscape, the company's focus on customer-centric innovation and financial strength position it well for future growth. With raised guidance and shareholder value initiatives, Zoetis is poised for continued success in the animal health industry.

Zoetis reports strong Q3 earnings and eyes sustained growth

Zoetis delivered robust operational growth in Q3 2024, driven by strong performance in key segments and products, leading to a revised full year guidance and confidence in future prospects.
Despite potential challenges in navigating a dynamic landscape and supply chain efficiency, Zoetis remains well-positioned to capitalize on opportunities for growth in 2025 through innovation and market expansion.
With a focus on sustained above-industry average growth, Zoetis' strategic strengths in key franchises and market positioning reinforce their leadership in the animal health industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The company was founded in 1952 and is headquartered in Parsippany, NJ.

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DEI--Zoetis Inc. (NYSE:ZTS) has been named to Fair360's Top 50 Companies list for the first time, underscoring the company's progress and sustained commitment to advancing Diversity, Equity and Inclusion (DE&I). Zoetis is the only animal health company included in this year's Top 50 rankings. “Zoetis' DE&I focus begins with our dedicated Board of Directors and executive team of diverse experiences, backgrounds, and perspectives, promoting an inclusive envir.

Zoetis Named a Top Company for DE&I by Fair360 (Formerly DiversityInc.)

Zacks.com users have recently been watching Zoetis (ZTS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is Trending Stock Zoetis Inc. (ZTS) a Buy Now?

Zoetis reported healthy beats on the top and bottom lines. Growth took place in both its U.S. and international segments, with the companion animal products business leading the way.

Zoetis Exceeds Q1 Earnings Expectations

NEW YORK , May 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zoetis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS

Zoetis is a leader in animal health, focusing on R&D to develop innovative medicines and technologies for pets and livestock. Concerns have arisen about the safety of their drugs, but Zoetis appears confident and reported impressive revenue growth. The stock experienced volatility but has since recovered, and the long-term outlook for Zoetis remains positive.

Zoetis: Long-Term Buy Despite Safety Concerns

Domino's Pizza

Global Payments

Mastercard

Monolithic Power Systems

MSCI

NIKE

Old Dominion Freight Line

Rollins

Ross Stores

Sherwin-Williams

Sirius XM Holdings Inc

SPDR S&P 500 ETF Trust

UnitedHealth Group

Visa

Vanguard Dividend Appreciation ETF

The SPDR S&P 500 ETF Trust had a 4.03% loss in April, slightly outperforming Vanguard's Dividend Appreciation Index Fund ETF Shares, -4.13%.

My Top 15 High Growth Dividend Stocks For May 2024

The animal health products purveyor unveiled its first-quarter results. It posted encouraging growth on both the top and bottom lines.

Why Zoetis Stock Popped by Almost 6% on Thursday

Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.

Zoetis (ZTS) Q1 Earnings and Revenues Surpass Estimates

Zoetis Inc (NYSE:ZTS ) Q1 2024 Results Conference Call May 2, 2024 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Michael Ryskin - Bank of America Jon Block - Stifel Erin Wright - Morgan Stanley David Westenberg - Piper Sandler Brandon Vazquez - William Blair Christopher LoBianco - TD Cowen Nathan Rich - Goldman Sachs Balaji Prasad - Barclays Glen Santangelo - Jefferies Chris Schott - JPMorgan Navann Ty - BNP Operator Welcome to the First Quarter 2024 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.

Zoetis Inc (ZTS) Q1 2024 Earnings Call Transcript

The headline numbers for Zoetis (ZTS) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics

Zoetis (ZTS) came out with quarterly earnings of $1.38 per share, beating the Zacks Consensus Estimate of $1.34 per share. This compares to earnings of $1.31 per share a year ago.

Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates

Animal healthcare company Zoetis surpassed analysts' expectations for first-quarter profit on Thursday, helped by strong demand for its medicines and vaccines for pets.

Zoetis beats profit estimates on strong demand for pet products

Zoetis earnings and sales slightly beat first-quarter estimates for the pet drugmaker. Shares rose modestly.

Zoetis Earnings Top; Pet Drugmaker Rises

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the first quarter of 2024 and updated its guidance for full year 2024. The company reported revenue of $2.2 billion for the first quarter of 2024, an increase of 10% compared with the first quarter of 2023. On an operational1 basis, revenue for the first quarter of 2024 increased 12% compared with the first quarter of 2023. Net income for the first quarter of 2024 was $599 million, or $1.31 per di.

Zoetis Announces First Quarter 2024 Results

Bristol-Myers

Monster Beverage

Value investors have been frustrated as growth stocks have outperformed for the past 15 years. Value investing is a long-term strategy that requires patience and a focus on fundamentals. Three blue-chip stocks, Bristol-Myers, Zoetis, and Monster Beverage, are trading at 52-week lows and may be attractive opportunities for value investors.

3 Blue-Chip Bargains Trading At 52-Week Lows

The animal health firm has had a tough year with shares down nearly 20% amid negative media reports about a key new medicine.

Zoetis Reports Earnings Thursday. The Company Must Address Dog Pain Drug Safety Worries.

IDEXX Laboratories

Nestle SA

Fortune.com recently reported that artificial intelligence (AI) is helping the pet care industry cope with a chronic veterinary shortage. AI use cases could become far more prevalent for pets than humans in the near term due to fewer impediments such as privacy laws.

Furry Tech Boom: 3 Pet Stocks Unleashing the Power of AI

Zoetis is the leader in the global animal healthcare industry. However, it has run into a trio of short-term issues.

1 Magnificent Dividend Growth Stock That's Down 40% and Trading at a Once-in-a-Decade Valuation

Besides Wall Street's top -and-bottom-line estimates for Zoetis (ZTS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Unveiling Zoetis (ZTS) Q1 Outlook: Wall Street Estimates for Key Metrics

Phibro Animal Health

PARSIPPANY, N.J. & TEANECK, N.J.--(BUSINESS WIRE)---- $PAHC #animalhealth--Zoetis Inc. (NYSE:ZTS) and Phibro Animal Health Corporation (Nasdaq: PAHC) today announced that they have entered into a definitive agreement where Phibro Animal Health will acquire Zoetis' medicated feed additive (MFA) product portfolio, certain water soluble products and related assets for $350 million, subject to customary closing adjustments. This transaction is expected to be complete in the second half of calendar year 2024. Both Zoetis a.

Zoetis to Sell Medicated Feed Additive Portfolio to Phibro Animal Health

NEW YORK , April 26, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zoetis Inc. (NYSE: ZTS) resulting from allegations that Zoetis may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zoetis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages Zoetis Inc. Investors to Inquire About Securities Class Action Investigation - ZTS

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Analysts Look Bullish on Zoetis (ZTS): Should You Buy?

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #DrivenToCare--As we celebrate World Veterinary Day, the Zoetis Foundation is proud to support veterinarians around the world today and everyday by providing grant support to initiatives promoting veterinary education, mental well-being, and livelihoods. Recognizing the invaluable role veterinarians and veterinary technicians play in advancing animal health, the Foundation is committed to helping cultivate a thriving, inclusive veterinary profession. “By investing in veterin.

Zoetis Foundation Champions Global Veterinarian Education, Well-being, and Livelihoods on World Veterinary Day and Beyond

In the latest trading session, Zoetis (ZTS) closed at $145.54, marking a -0.66% move from the previous day.

News for Zoetis Stock (ZTS)